KR20220042182A - 3,6-디아미노-피리다진-3-일 유도체, 이를 함유하는 약학적 조성물 및 아폽토시스 유발제로서의 용도 - Google Patents

3,6-디아미노-피리다진-3-일 유도체, 이를 함유하는 약학적 조성물 및 아폽토시스 유발제로서의 용도 Download PDF

Info

Publication number
KR20220042182A
KR20220042182A KR1020227006624A KR20227006624A KR20220042182A KR 20220042182 A KR20220042182 A KR 20220042182A KR 1020227006624 A KR1020227006624 A KR 1020227006624A KR 20227006624 A KR20227006624 A KR 20227006624A KR 20220042182 A KR20220042182 A KR 20220042182A
Authority
KR
South Korea
Prior art keywords
methyl
amino
propyl
thiazole
benzothiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227006624A
Other languages
English (en)
Korean (ko)
Inventor
제임스 에드워드 폴 데이비슨
티보르 노박
아틸라 팍잘
안드라스 코트치
제롬-베누아 스탁
제임스 브룩 머레이
사이먼 베드포드
마이아 찬리온
프레데릭 콜랜드
파트리스 데소스
마크 필립 도즈워스
패트라 던켈
안드라스 헤르너
졸탄 마다라스
아나 레티시아 마라그노
마크 몰나르
미클로스 니에르게스
레이첼 제인 파슨스
모니카 루다소바
아그네스 스트로팩
마리아나 시게티
마티아스 팔 티마리
폴 웹
Original Assignee
르 라보레또레 쎄르비에르
베르날리스 (알 앤드 디) 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 르 라보레또레 쎄르비에르, 베르날리스 (알 앤드 디) 리미티드 filed Critical 르 라보레또레 쎄르비에르
Publication of KR20220042182A publication Critical patent/KR20220042182A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020227006624A 2019-07-29 2020-07-28 3,6-디아미노-피리다진-3-일 유도체, 이를 함유하는 약학적 조성물 및 아폽토시스 유발제로서의 용도 Pending KR20220042182A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19188747.0 2019-07-29
EP19188747 2019-07-29
PCT/EP2020/071179 WO2021018857A1 (en) 2019-07-29 2020-07-28 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents

Publications (1)

Publication Number Publication Date
KR20220042182A true KR20220042182A (ko) 2022-04-04

Family

ID=67514281

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227006624A Pending KR20220042182A (ko) 2019-07-29 2020-07-28 3,6-디아미노-피리다진-3-일 유도체, 이를 함유하는 약학적 조성물 및 아폽토시스 유발제로서의 용도

Country Status (24)

Country Link
US (1) US20220289734A1 (https=)
EP (1) EP4003988A1 (https=)
JP (1) JP7646626B2 (https=)
KR (1) KR20220042182A (https=)
CN (1) CN114450283B (https=)
AR (1) AR119493A1 (https=)
AU (1) AU2020322072A1 (https=)
BR (1) BR112022001330A2 (https=)
CA (1) CA3148502A1 (https=)
CL (1) CL2021003594A1 (https=)
CO (1) CO2022000700A2 (https=)
CR (1) CR20220014A (https=)
DO (1) DOP2022000015A (https=)
GE (2) GEAP202415866A (https=)
IL (1) IL289932B2 (https=)
JO (1) JOP20220006A1 (https=)
MX (1) MX2022001161A (https=)
PE (1) PE20220704A1 (https=)
PH (1) PH12022550018A1 (https=)
PY (1) PY2039849A (https=)
SA (1) SA522431498B1 (https=)
TW (1) TWI900486B (https=)
UY (1) UY38809A (https=)
WO (1) WO2021018857A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021386367A1 (en) * 2020-11-24 2023-06-22 Les Laboratoires Servier Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
JP2024505562A (ja) * 2021-02-02 2024-02-06 レス ラボラトイレス セルビエル 選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法
CN119562832A (zh) 2022-05-20 2025-03-04 诺华股份有限公司 Met bcl-xl抑制剂抗体-药物缀合物及其使用方法
AU2023271885A1 (en) 2022-05-20 2024-12-12 Les Laboratoires Servier Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
US20250387504A1 (en) 2022-05-20 2025-12-25 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
PY24103486A (es) 2023-11-22 2025-06-06 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
AR134424A1 (es) 2023-11-22 2026-01-14 Novartis Ag Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059354A2 (en) * 2001-12-21 2003-07-24 Bayer Pharmaceuticals Corporation Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
WO2009020603A2 (en) * 2007-08-08 2009-02-12 The Scripps Research Institute Upp amphiphilic alpha-helix mimetics
EA201001030A1 (ru) * 2007-12-19 2011-02-28 Амген Инк. Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла
FR3015483B1 (fr) 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SG11201709837RA (en) * 2015-05-29 2017-12-28 Teijin Pharma Ltd PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

Also Published As

Publication number Publication date
EP4003988A1 (en) 2022-06-01
CR20220014A (es) 2022-03-02
SA522431498B1 (ar) 2025-04-13
TW202118761A (zh) 2021-05-16
CL2021003594A1 (es) 2022-11-18
US20220289734A1 (en) 2022-09-15
DOP2022000015A (es) 2022-05-15
WO2021018857A1 (en) 2021-02-04
BR112022001330A2 (pt) 2022-05-17
JP2022542937A (ja) 2022-10-07
UY38809A (es) 2021-02-26
AU2020322072A1 (en) 2022-02-10
IL289932A (en) 2022-03-01
CA3148502A1 (en) 2021-02-04
CO2022000700A2 (es) 2022-02-07
MX2022001161A (es) 2022-02-22
IL289932B1 (en) 2025-10-01
CN114450283A (zh) 2022-05-06
GEP20247670B (en) 2024-09-25
JOP20220006A1 (ar) 2023-01-30
GEAP202415866A (en) 2024-06-10
NZ784583A (en) 2025-02-28
IL289932B2 (en) 2026-02-01
PE20220704A1 (es) 2022-05-04
PY2039849A (es) 2021-05-06
PH12022550018A1 (en) 2022-10-17
CN114450283B (zh) 2024-05-07
TWI900486B (zh) 2025-10-11
AR119493A1 (es) 2021-12-22
JP7646626B2 (ja) 2025-03-17

Similar Documents

Publication Publication Date Title
JP7805283B2 (ja) ガンを処置するためのｂｃｌ－ｘｌタンパク質阻害剤及びアポトーシス促進剤としての、６，７－ジヒドロ－５ｈ－ピリド［２，３－ｃ］ピリダジン誘導体及び関連化合物。
JP7646626B2 (ja) ３，６－ジアミノ－ピリダジン－３－イル誘導体、それを含有する医薬組成物及びアポトーシス促進剤としてのその使用
KR102030609B1 (ko) Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
US20220315597A1 (en) Tricyclic compounds and their use
CA3213388A1 (en) Macrocyclic lrrk2 kinase inhibitors
US20240374606A1 (en) Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer
EP4403558A1 (en) Azaindazole macrocyclic compound and use thereof
RU2830186C2 (ru) 3,6-диаминопиридазин-3-ильные производные, содержащие их фармацевтические композиции и их применение в качестве проапоптотических средств
RU2832191C2 (ru) 6,7-дигидро-5h-пиридо[2,3-c]пиридазиновые производные и родственные соединения в качестве ингибиторов белков bclxl и проапоптотических средств для лечения злокачественных новообразований
WO2022150446A1 (en) Tyk2 inhibitors
EA046336B1 (ru) 3,6-диаминопиридазин-3-ильные производные, содержащие их фармацевтические композиции и их применение в качестве проапоптотических средств
OA20487A (en) 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents.
EA052683B1 (ru) 6,7-ДИГИДРО-5H-ПИРИДО[2,3-c]ПИРИДАЗИНОВЫЕ ПРОИЗВОДНЫЕ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕЛКОВ BCL-XL И ПРОАПОПТОТИЧЕСКИХ СРЕДСТВ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ
HK40068269A (en) 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents
HK40074798A (en) 6,7-dihydro-5h-pyrido[2,3-c]pyridazine derivatives and related compounds as bcl-xl protein inhibitors and pro-apoptotic agents for treating cancer
HK40074798B (en) 6,7-dihydro-5h-pyrido[2,3-c]pyridazine derivatives and related compounds as bcl-xl protein inhibitors and pro-apoptotic agents for treating cancer
HK40068269B (zh) 3，6-二氨基-哒嗪-3-基衍生物、含有它们的药物组合物及其作为促凋亡剂的用途
HK40074219A (en) 6,7-dihydro-5h-pyrido[2,3-c]pyridazine derivatives and related compounds as bcl-xl protein inhibitors and pro-apoptotic agents for treating cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701